When investigating outcomes, such as response to anti-EGFR therapy, it may be more beneficial to choose a cutoff score leading to high sensitivity rather than specificity for tumour response to select the greatest number of potentially responsive candidates for treatment. Here, EGFR is linked to neoplasm.